In the first weeks of his tenure as FDA commissioner, Scott Gottlieb, MD, is taking action on the issue he had vowed to make his “highest initial priority:” fighting the opioid abuse epidemic and stopping the waves of overdoses across the nation.
In the first weeks of his tenure as FDA commissioner, Scott Gottlieb, MD, is taking action on the issue he had vowed to make his “highest initial priority:” fighting the opioid abuse epidemic and stopping the waves of overdoses across the nation.
In an open letter published on the FDA Voice blog, Gottlieb outlines his plans for the FDA to step up its role in preventing and curtailing opioid abuse. For instance, he writes that the agency has the authority and moral obligation to ensure opioids are prescribed appropriately to patients who truly need them.
A major step is the creation of an Opioid Policy Steering Committee, comprised of the FDA’s experienced career faculty members who will be tasked with brainstorming and investigating any potential steps the agency can implement. There will likely be several approaches on the table, as Gottlieb has encouraged the committee members to “go in whatever direction the scientific and public health considerations lead.” This direction will find its inital guide in the answers to the following questions:
Gottlieb’s letter cited statistics on the scope of the opioid crisis, and its staggering costs, to demonstrate the need for urgent and decisive action. For instance, a survey of heroin users in treatment found that for 3 out of 4, their addiction had started with prescription opioid drugs. Furthermore, the risk of continuing to use opioids for over 1 year is 6% for patients prescribed a 1-day supply of opioids, but 35% for those prescribed a 30-day supply.
In addition to the recommendations of the Steering Committee and other FDA officials, the agency is reaching out to the public for suggestions on tackling the crisis.
“I look forward to working closely with my FDA colleagues as we quickly move forward, capitalizing on good work that has already been done, and expanding those efforts in novel directions,” Gottlieb concluded.
The opioid crisis has been a prominent concern for the FDA and its new leader. In Gottlieb’s Senate confirmation hearing, he described it as a “staggering human tragedy that will require dramatic action.” After being sworn in as commissioner, Gottlieb’s speech to FDA staff indicated he would take immediate action to develop a multifaceted strategy that would define the agency’s role in mitigating the epidemic.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More